Endovascular Treatment for eXtra-Large Ischemic Stroke

Launched by ZHONGMING QIU · Apr 24, 2024

Keywords

ClinConnect Summary

The XL STROKE-2 clinical trial is studying a treatment called endovascular thrombectomy, which is a procedure used to remove blood clots from the brain in patients who have experienced a large ischemic stroke. This type of stroke occurs when a blood vessel supplying blood to the brain becomes blocked, and it can lead to significant brain damage if not treated quickly. The trial aims to determine if this procedure is safe and effective for patients with a particularly large area of brain affected by the stroke.

To participate in this trial, individuals must be 18 years or older, have experienced an acute ischemic stroke within the last 6 hours, and have specific types of blood vessel blockages confirmed by imaging tests. However, people with certain conditions, like bleeding disorders or severe illness, may not be eligible. Participants will receive the thrombectomy procedure and will be monitored for their recovery. This research is important because it may help improve treatment options for patients with severe strokes, potentially leading to better outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older, and modified Rankin scale score = 0 or 1 in patients 80 years or older;
• • 2. Acute ischemic stroke within 6 hours from last known well to randomization, or with negative MRI-FLAIR (no change on FLAIR sequence and presence of infarct on MRI-DWI) if \> 6 hours or unknown last known well time;
• • 3. Occlusion of the internal carotid artery, M1 or M2 segment of the middle cerebral artery confirmed by CTA/MRA/DSA;
• • 4. Baseline ASPECTS score of 0-2 or infarct core volume ≥100ml;
• • 5. The patient or patient's representative signs a written informed consent form.
• Exclusion Criteria:
• • 1. CT or MR evidence of hemorrhage;
• • 2. Evidence of mass effect with ventricular effacement, midline shift or herniation on baseline imaging;
• • 3. Vessel tortuosity where it is expected that the thrombectomy device will not be able to reach the occlusion site or result in unstable access;
• • 4. History of bleeding disorders, severe heart, liver or kidney disease, or sepsis;
• • 5. Currently participating in another investigational drug study;
• • 6. Any terminal illness with life expectancy less than 6 months.